These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 32384313)

  • 61. A child with severe head banging.
    Granana N; Tuchman RF
    Semin Pediatr Neurol; 1999 Sep; 6(3):221-4. PubMed ID: 10522343
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Fluoxetine treatment of obsessive-compulsive disorder: an open clinical trial.
    Liebowitz MR; Hollander E; Schneier F; Campeas R; Hatterer J; Papp L; Fairbanks J; Sandberg D; Davies S; Stein M
    J Clin Psychopharmacol; 1989 Dec; 9(6):423-7. PubMed ID: 2687337
    [TBL] [Abstract][Full Text] [Related]  

  • 63. A review of the efficacy of selective serotonin reuptake inhibitors in obsessive-compulsive disorder.
    Pigott TA; Seay SM
    J Clin Psychiatry; 1999 Feb; 60(2):101-6. PubMed ID: 10084636
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Effects of tryptophan depletion on selective serotonin reuptake inhibitor-remitted patients with obsessive compulsive disorder.
    Hood SD; Broyd A; Robinson H; Lee J; Hudaib AR; Hince DA
    J Psychopharmacol; 2017 Dec; 31(12):1615-1623. PubMed ID: 29095069
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Psychosocial treatment for obsessive-compulsive disorder.
    Munford PR; Hand I; Liberman RP
    Psychiatry; 1994 May; 57(2):142-52. PubMed ID: 7938333
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Serotonin syndrome: a case report.
    Likasitwattanakul S
    J Med Assoc Thai; 2005 Jul; 88(7):993-6. PubMed ID: 16241032
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Selective serotonin reuptake inhibitors, and serotonin and norepinephrine reuptake inhibitors for anxiety, obsessive-compulsive, and stress disorders: A 3-level network meta-analysis.
    Gosmann NP; Costa MA; Jaeger MB; Motta LS; Frozi J; Spanemberg L; Manfro GG; Cuijpers P; Pine DS; Salum GA
    PLoS Med; 2021 Jun; 18(6):e1003664. PubMed ID: 34111122
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Possible Toxic Serotonin Syndrome in an Adolescent With Obsessive-Compulsive Disorder Precipitated by Esomeprazole.
    Naguy A; Singh A; AlDarweesh FQM; Alamiri B
    Prim Care Companion CNS Disord; 2022 Jul; 24(4):. PubMed ID: 35878563
    [No Abstract]   [Full Text] [Related]  

  • 69. Obsessive-compulsive disorder, trichotillomania, and anorexia nervosa: a case report.
    Pryor TL; Martin RL; Roach N
    Int J Eat Disord; 1995 Dec; 18(4):375-9. PubMed ID: 8580925
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Delayed obsessive-compulsive disorder symptom exacerbation after a single dose of a serotonin antagonist in fluoxetine-treated but not untreated patients.
    Greenberg BD; Benjamin J; Martin JD; Keuler D; Huang SJ; Altemus M; Murphy DL
    Psychopharmacology (Berl); 1998 Dec; 140(4):434-44. PubMed ID: 9888619
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Disinhibition as a side effect of treatment with fluvoxamine in pediatric patients with obsessive-compulsive disorder.
    Harris E; Eng HY; Kowatch R; Delgado SV; Saldaña SN
    J Child Adolesc Psychopharmacol; 2010 Aug; 20(4):347-53. PubMed ID: 20807074
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Efficacy of long-term fluoxetine treatment of obsessive-compulsive disorder.
    Frenkel A; Rosenthal J; Nezu A; Winston A
    Mt Sinai J Med; 1990 Nov; 57(6):348-52. PubMed ID: 2079952
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Gabapentin augmentation for fluoxetine-treated patients with obsessive-compulsive disorder.
    Corá-Locatelli G; Greenberg BD; Martin J; Murphy DL
    J Clin Psychiatry; 1998 Sep; 59(9):480-1. PubMed ID: 9771822
    [No Abstract]   [Full Text] [Related]  

  • 74. Olanzapine augmentation for treatment-resistant obsessive-compulsive disorder.
    Koran LM; Ringold AL; Elliott MA
    J Clin Psychiatry; 2000 Jul; 61(7):514-7. PubMed ID: 10937610
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Early onset of response with selective serotonin reuptake inhibitors in obsessive-compulsive disorder: a meta-analysis.
    Issari Y; Jakubovski E; Bartley CA; Pittenger C; Bloch MH
    J Clin Psychiatry; 2016 May; 77(5):e605-11. PubMed ID: 27249090
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Fluvoxamine in the treatment of obsessive compulsive disorder.
    Montgomery SA; Manceaux A
    Int Clin Psychopharmacol; 1992 Jun; 7 Suppl 1():5-9. PubMed ID: 1355499
    [TBL] [Abstract][Full Text] [Related]  

  • 77. [Compulsive-obsessive disorder after severe head trauma: diagnosis and treatment].
    Stengler-Wenzke K; Müller U; Matthes-von-Cramon G
    Psychiatr Prax; 2003 Jan; 30(1):37-9. PubMed ID: 12524581
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Aripiprazole augmentation in treatment-refractory obsessive-compulsive disorder.
    Sarkar R; Klein J; Krüger S
    Psychopharmacology (Berl); 2008 May; 197(4):687-8. PubMed ID: 18264798
    [No Abstract]   [Full Text] [Related]  

  • 79. Sertraline induced cervical dystonia in a patient of Obsessive Compulsive Disorder.
    Gupta B; Ahmad J; Kar SK; Shrivastava A
    Asian J Psychiatr; 2018 Jan; 31():77-78. PubMed ID: 29447992
    [No Abstract]   [Full Text] [Related]  

  • 80. Sertraline and tic: case report.
    Ghanizadeh A
    Pharmacopsychiatry; 2007 Nov; 40(6):289-90. PubMed ID: 18030654
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.